Medgenics intends to price public offering of common stock

Maxim Group leads underwriters; shares sold with five-year warrants

By Toni Weeks

San Diego, Jan. 17 - Medgenics, Inc. said it will price a public offering of common stock, according to a 424B5 filing with the Securities and Exchange Commission. The deal will have a 45-day greenshoe.

The shares will be sold with five-year series 2013-A warrants.

Maxim Group LLC is the bookrunning manager. National Securities Corp. and MLV & Co. are additional underwriters.

Proceeds will be used for product development activities, patient maintenance fees, intellectual property support, general corporate purposes and working capital.

Medgenics, a San Francisco-based medical technology and therapeutics company, has developed the Biopump Platform Technology to continuously produce and deliver therapeutic proteins under a patient's skin.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.